Session II: Mass Spectrometry in Cell & Gene Therapy

Session Chairs: : Rich Rogers, Umoja Biopharma and Chris Yu, Genentech, A Member of the Roche Group

Mass spectrometry (MS) has emerged as a powerful analytical tool in the field of cell and gene therapy. As these therapies continue to revolutionize medicine, understanding their complex processes and ensuring consistent product quality become critical objectives. In this session, we explore how MS-based analytical technologies are advancing our understanding and the manufacturing of cell and gene therapy drug products.

Session Speakers:

A Novel In-Vitro Expression LC/MS/MS Assay for mRNA Vaccine Characterization

Olga Friese, Pfizer, Inc.

Characterising Viral Vectors for Gene Therapy using Mass Spectrometry on Different Levels

Jonathan Bones, NIBRT

Enabling Biopharmaceutical Applications of Electrostatic Linear Ion Trap Charge Detection Mass Spectrometry (ELIT-CDMS)

Rebecca D’Esposito, Waters Corporation